M&A Deal Summary

Novoheart Holdings Acquires Xellera Therapeutics

On May 28, 2019, Novoheart Holdings acquired life science company Xellera Therapeutics for 34M CAD

Acquisition Highlights
  • This is Novoheart Holdings’ 1st transaction in the Life Science sector.
  • This is Novoheart Holdings’ 0th largest (disclosed) transaction.
  • This is Novoheart Holdings’ 1st transaction in China.

M&A Deal Summary
Date 2019-05-28
Target Xellera Therapeutics
Sector Life Science
Buyer(s) Novoheart Holdings
Deal Type Add-on Acquisition
Deal Value 34M CAD

Target

Xellera Therapeutics

Hong Kong, China
website
Xellera Therapeutics Ltd. is dedicated to developing cell- and gene-based therapies. XT’s mission is to bring advanced therapeutic options to patients in an era of precision medicine. XT is focused on building a Good Manufacturing Practice (GMP) facility for generating clinical-grade human stem cell lines, initially within the Southern Chinese population. The goal of these clinical-grade stem cell libraries will be to enable quicker identification of suitable donor material for cell-based therapies, minimizing the wait and avoiding complications commonly associated with transplantation, such as immune rejection or side effects caused by immunosuppression.

Search 194,640 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novoheart Holdings

Vancouver, British Columbia, Canada

website

Category Company
Sector Life Science
DESCRIPTION

Novoheart Holdings, Inc. is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. Novoheart Holdings, Inc. have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients. Novoheart Holdings is based in Vancouver, British Columbia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (China) 1 of 1
Year (2019) 1 of 1
Mergr

Product

Company

Legal